Systemic sclerosis/scleroderma: A treatable multisystem disease

American Family Physician

Volumn 78, Issue 8, 2008, Pages

  Hinchcliff, Monique ^a,b   Varga, John ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b M300   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTACID AGENT; AUTOANTIBODY; AZATHIOPRINE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; ILOPROST; LONG ACTING DRUG; LOSARTAN POTASSIUM; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; PENICILLAMINE; PENTOXIFYLLINE; PHOSPHODIESTERASE V INHIBITOR; PRAZOSIN; PREDNISONE; PROSTACYCLIN; PROTON PUMP INHIBITOR; RIFAXIMIN; SILDENAFIL; UNINDEXED DRUG; UNIPROST; WARFARIN;

ANTIBIOTIC THERAPY; ANTIBODY PRODUCTION; BARRETT ESOPHAGUS; BLADDER CANCER; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; DRUG MEGADOSE; EARLY DIAGNOSIS; GASTROESOPHAGEAL REFLUX; HEMATOLOGIC MALIGNANCY; HEMORRHAGIC CYSTITIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HYPERTENSION; INFECTION; INFERTILITY; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; KIDNEY INJURY; LABORATORY TEST; LIFESTYLE MODIFICATION; LUNG EMBOLISM; LUNG FUNCTION TEST; PRACTICE GUIDELINE; PROGNOSIS; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; RISK FACTOR; SCLERODERMA; SKIN FIBROSIS; SKIN INDURATION; SKIN ULCER; SURVIVAL RATE; SYSTEMIC SCLEROSIS; UNSPECIFIED SIDE EFFECT; ARTHRALGIA; ARTICLE; DYSPHAGIA; DYSPNEA; HEART DISEASE; LUNG DISEASE;

ARTHRALGIA; DEGLUTITION DISORDERS; DIAGNOSIS, DIFFERENTIAL; DYSPNEA; GASTROESOPHAGEAL REFLUX; HEART DISEASES; HUMANS; KIDNEY DISEASES; LUNG DISEASES; PROGNOSIS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC;

EID: 56149118477     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Silman AJ, Hochberg MC, Cooper C, et al. Epidemiology of the Rheumatic Diseases. Oxford, U.K.: Oxford University Press; 1993:192.
2. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41(5):778-799.
3. Steen VD, Lucas M, Fertig N, Medsger TA Jr. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic scelrosis patients with a nucleolar antibody. J Rheumatol. 2007;34(11):2230-2235.
4. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35(1):35-42.
5. Steen VD, Medsger TA JR. The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis. Arthritis Rheum. 1997;40(6):1146-1151.
6. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994;37(9):1283-1289.
7. Proudman SM, Stevens WM, Sahhar J, Celermajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J. 2007;37(7):485-494.
8. van Laar JM, Stolk J, Tyndall A. Scleroderma lung: pathogenesis, evaluation and current therapy. Drugs. 2007;67(7):985-996.
9. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis. 2003;62(2):97-99.
10. Chang B, Schachna L, White B, Wigley FM, Wise RA. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol. 2006;33(2):269-274.
11. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am. 2003;29(2):315-333.
12. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43(11):2437-2444.
13. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998;41(9):1613-1619.
14. Steen VD. Pregnancy in scleroderma. Rheum Dis Clin North Am. 2007;33(2):345-358.
15. Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988;31(2):196-203.
16. Traub YM, Shapiro AP, Rodnan GP, et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore). 1983;62(6):335-352.
17. Champion HC. The heart in scleroderma. Rheum Dis Clin North Am. 2008;34(1):181-190.
18. Aguglia G, Sgreccia A, Bernardo ML, et al. Left ventricular diastolic function in systemic sclerosis. J Rheumatol. 2001;28(7):1563-1567.
19. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud phenomenon in systemic sclerosis. Arthritis Rheum. 2001;44(8):1841-1847.
20. Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum. 1999;42(12):2646-2655.
21. Fries R, Shariat K, von Wilmowsky H, Böhm M. Sildenafil in the treatment of Raynaud phenomenon resistant to vasodilatory therapy. Circulation. 2005;112(19):2980-2985.
22. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50(12):3985-3993.
23. Pope J, Fenlon D, Thompson A, et al. Prazosin for Raynaud phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;(2): CD000956.
24. Quigley EM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology. 2006;130 (2 suppl 1):S78-S90.
25. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25): 2655-2666.
26. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54(12):3962-3970.
27. Khanna D, Yan X, Tashkin DP, et al. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum. 2007;56(5):1676-1684.
28. Jain M, Varga J. Mycophenolate mofetil: a promising novel therapy in systemic sclerosis. Curr Rheumatol Rep. 2007;9(2):133-135.
29. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease. Ann Rheum Dis. 2006;65(10):1336-1340.
30. McLaughlin VV. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur J Clin Invest. 2006;(36 suppl 3):10-15.
31. Oudiz RJ, Schilz RJ, Barst RJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004;126(2):420-427.
32. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003;41(2):293-299.
33. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002;165(6): 800-804.
34. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132(6):425-434.
35. Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med. 2000;133(8):600-603.